^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR mutation + LINC00460 overexpression

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor, LINC00460, Long Intergenic Non-Protein Coding RNA 460, NONHSAG014130.2, HSALNG0099182, LINC00460
    Entrez ID:
    1956; 728192
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Upregulation of long non‑coding RNA LINC00460 in EGFR‑mutant lung cancer indicates a poor prognosis in patients treated with osimertinib. (PubMed, Oncol Lett)
    Moreover, following osimertinib therapy, PFS was significantly shorter for patients with high LINC00460 expression in plasma cell-free RNA (n=12) than for those with low LINC00460 expression (n=12) (median PFS: 655 days vs. 210 days; P=0.020). In conclusion, the upregulation of LINC00460, the expression of which is implicated in osimertinib resistance, in the primary site and plasma of patients with EGFR mutation-positive lung cancer may be associated with a poor prognosis in those treated with osimertinib.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • LINC00460 (Long Intergenic Non-Protein Coding RNA 460)
    |
    EGFR mutation • EGFR expression • EGFR mutation + LINC00460 overexpression
    |
    Tagrisso (osimertinib)